[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Languages
Last Updated: Thursday, 8 July, 2004, 13:33 GMT 14:33 UK
China overturns Viagra patent
By Francis Markus
BBC correspondent, Shanghai

Viagra
China's decision could have far-reaching consequences
Officials in China have defended their decision to overturn a patent on the anti-impotence drug, Viagra.

Viagra is made by the world's biggest drug company, the American pharmaceutical giant Pfizer.

US business groups have condemned the decision, which they say has far-reaching implications.

But some Aids activists hope it could spell good news for Chinese people with HIV/Aids.

Sources at China's state intellectual property office said Pfizer had failed to provide enough information on exactly how the active ingredient - a substance called Sildenafil Sitrate - was manufactured.

It said several Chinese companies had filed complaints, and the authorities had now ruled in favour of allowing them to copy the drug.

Pfizer is reported to be appealing against the decision, arguing that it was not asked for the information when the patent was granted, three years ago.

US business lobby groups have condemned China's decision as making a mockery of its commitments under World Trade Organization rules to protect intellectual property.

On the other hand, one Aids activist said the move was potentially good news if it signalled a tougher Chinese line on the pharmaceuticals that might help to make foreign-patented anti-retroviral drugs available cheaply for Chinese people with HIV/Aids.




SEE ALSO:
Imports 'cost drug firms 770m'
22 Mar 04  |  Business
Internet drug warning
13 Aug 02  |  Health


RELATED INTERNET LINKS:
The BBC is not responsible for the content of external internet sites


PRODUCTS AND SERVICES

News Front Page | Africa | Americas | Asia-Pacific | Europe | Middle East | South Asia
UK | Business | Entertainment | Science/Nature | Technology | Health
Have Your Say | In Pictures | Week at a Glance | Country Profiles | In Depth | Programmes
Americas Africa Europe Middle East South Asia Asia Pacific